Search results for "CDMO; gene therapy; process develop…"

Article CDMOs Driving Emerging Bio/Pharma Success
CDMOs Driving Emerging Bio/Pharma Success CDMOs can claim credit for the robust growth of emerging bio/pharma financings. By Jim Miller Emerging bio/pharmaceutical companie…

Article The Role of CDMOs in Cell and Gene Therapy Process Development
Click here to read more >> An experienced contract development and manufacturing organization (CDMO) can ease scaling and tech transfer.

Article Step Up to GMP Manufacturing or Outsource to a CDMO: Considerations and Tips
Whether you are developing a new monoclonal antibody (mAb), cell therapy, gene therapy, or large-molecule biologic drug, the decision to tackle GMP manufacturing in-house or work with a contract devel…

Article Mapping a Route for Cell and Gene Therapy Process Development
While cell and gene therapies differ in many ways, some of the best practices for process development and validation are similar. By Cynthia A. Challener …

Article Gene Therapies Push Viral Vector Production
Gene Therapies Push Viral Vector Production Viral vectors show promise as a delivery mechanism for gene therapy, but which virus types are commercially viable? By Feliza Miraso…

Article Maximum Output Starts with Optimized Upstream Processing
By Cynthia A. Challener Biopharmaceutical companies and contract manufacturers respond to changing demand dynamics for upstream bioprocessing capacity. Significant growth in the develo…

Article Genetic Vaccine Platforms Demonstrate Their Potential
In a pandemic, genetic vaccines offer several advantages over traditional approaches. By Cynthia A. Challener For a vaccine to be effective, the components of the disease o…

Article Commercial Production of Gene Therapies Using Suspension or Adherent Cell Lines
This article will explore the traditional path from the laboratory to the clinic and how the fixed-bed technology provides an alternative solution to meet commercial demands. By Alex Chatel and …

Article Updating Viral Clearance for New Biologic Modalities
Viral clearance processes and guidance must evolve along with newer biotherapeutic modalities. By Feliza Mirasol Ensuring viral clearance (i.e., removal) in downstream purification has becom…

Article Flexible Facilities for Viral Vector Manufacturing
Single-use and modular systems will meet demand for rapid implementation at different scales.  By Jennifer Markarian Industry experts have noted that there are limitations in the…

Next Page